Business
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
SOUTH SAN FRANCISCO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary. Sanam most recently served as Senior Vice President, Legal of Alumis. In her new role, she will lead all legal and compliance functions, including corporate governance, intellectual property, a
About this update from Alumis Inc.
[{"type":"image","alt":"Alumis Inc.","displaySize":"","headline":null,"caption":"Alumis Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/cd047612371c6f86746cf01631a6f911"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D1V_aGoKejvy_01T3BfhbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cd047612371c6f86746cf01631a6f911","width":150,"height":39}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary. Sanam most recently served as Senior Vice President, Legal of Alumis. In her new role, she will lead all legal and compliance functions, including corporate governance, intellectual property, and strategic advisory on key decisions and transactions. Sanam succeeds Sara Klein, following her retirement from the company.","length":631,"tagName":"p"},{"type":"text","content":"“We’re thrilled to elevate Sanam to the role of Chief Legal Officer,” said Martin Babler, President and Chief Executive Officer of Alumis. “She brings a sharp legal and business mind and has already proven to be an invaluable member of our senior executive team. Her counsel and leadership will be essential as we advance our late-stage pipeline and continue our mission to transform the lives of people living with immune-mediated diseases.”","length":442,"tagName":"p"},{"type":"text","content":"“I also want to extend my deep gratitude to Sara, who has been with Alumis since the early days and played a pivotal role in our growth—including leading us through our IPO, our transition to a public company, and our merger with ACELYRIN. On behalf of the entire team, we thank Sara for her many contributions and wish her all the best in her retirement.”","length":356,"tagName":"p"},{"type":"text","content":"Prior to joining Alumis in September 2024, Sanam served in various leadership roles at ACELYRIN, Inc., most recently as Chief Legal Officer and Head of People. She previously held senior legal roles at companies across the biopharmaceutical, technology, and ren...